Can-Fite BioPharma Ltd. Stock Price, News & Analysis

Can-Fite BioPharma Ltd. (NYSE American: CANF) has signed an exclusive distribution agreement with Ewopharma for its drugs Piclidenoson and Namodenoson. The agreement includes an upfront payment of $2.25 million and potential milestone payments of up to $40.45 million, along with 17.5% royalties on net sales. Piclidenoson is aimed at treating psoriasis, while Namodenoson targets liver diseases like hepatocellular carcinoma (HCC) and NASH. This partnership offers Can-Fite immediate access to Central Eastern European markets and non-dilutive funding.

Can-Fite BioPharma Ltd. (NYSE American: CANF) has commenced a Phase II COVID-19 study, enrolling the first of 40 patients. The study, randomized and double-blind, evaluates Piclidenoson combined with standard supportive care versus placebo in hospitalized patients with moderate to severe COVID-19. Efficacy assessments will occur at Day 29, focusing on clinical status and safety data. Piclidenoson is a first-in-class treatment with proven anti-inflammatory effects, also being tested in psoriasis trials. The company's lead drug is positioned in multi-billion dollar markets addressing cancer and liver diseases.

Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced promising results from its Phase II study of Namodenoson for advanced liver cancer, showcasing nearly 4 years of overall survival in two patients, with notable improvements in ascites and liver function. The FDA and EMA approved the pivotal Phase III trial design, which plans to enroll 450 patients. Namodenoson holds Orphan Drug Designation and Fast Track Status in the U.S. This development marks a significant step towards a New Drug Application for hepatocellular carcinoma treatment.

Can-Fite BioPharma (NYSE American: CANF) announced the successful completion of pre-clinical studies showing that its CBD-rich T3/C15 cannabis fraction has an inhibitory effect on liver fibrosis. This condition, associated with severe liver diseases like NAFLD and HCC, involves the excessive buildup of scar tissue in the liver. The studies revealed that the therapeutic effects are mediated through the A3 adenosine receptor (A3AR). Can-Fite's drug candidate Namodenoson is progressing to pivotal Phase III trials for liver cancer and Phase IIb for NASH, with patent applications filed for cannabinoid-based therapies.

Can-Fite BioPharma (NYSE American: CANF, TASE: CFBI) has published a webinar focusing on its drug candidate Namodenoson for treating NASH, hosted by CEO Dr. Pnina Fishman and featuring KOL Dr. Stephen Harrison. Namodenoson successfully completed a Phase II study for NAFLD/NASH, and the company is preparing a Phase IIb study. Dr. Harrison emphasized the drug's potential in treating NASH, especially in high-risk patients. Can-Fite is actively pursuing regulatory pathways for accelerated approval based on its clinical results.

Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) announced the publication of a scientific paper on its drug Namodenoson for advanced hepatocellular carcinoma (HCC) with Child-Pugh B cirrhosis. Although the Phase II trial did not meet its primary endpoint, it showed significant survival benefits for patients with a CPB score of 7, with some patients remaining under treatment for over 3.5 years. The FDA and EMA have approved the protocol for a Phase III study. Namodenoson has received Orphan Drug and Fast Track Designation from the FDA.

Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) has received approval from Israel's Ministry of Health to conduct pre-clinical studies on cannabinoid fractions at nanomolar concentrations. This assessment aims to explore effects on cancer, inflammatory, and fat cells, potentially minimizing the adverse effects associated with higher concentrations. Can-Fite's research will be conducted in its labs, utilizing patent-pending formulations and assays. The medical cannabis market, projected to grow at a CAGR of 29%, positions Can-Fite strategically for advancements in this emerging field.

Can-Fite BioPharma Ltd. (NYSE American: CANF) announced progress on its drug candidate Namodenoson for treating non-alcoholic steatohepatitis (NASH). The company is designing a Phase IIb study with expert collaboration, following a successful Phase II study. Manufacturing for the clinical trial is complete, and new NASH patents have been issued. Namodenoson is licensed for distribution in Korea and China, targeting a growing market projected at $35-40 billion by 2025. Current estimates indicate 17%-33% of the U.S. population has non-alcoholic fatty liver disease (NAFLD), emphasizing the urgent medical need.

Can-Fite BioPharma (NYSE American: CANF) announced its participation in the 12th annual LD 500 Virtual Conference, scheduled for September 1, 2020. CEO Dr. Pnina Fishman will present at 9:20 AM EST and conduct private meetings with investors. The event aims to attract around 20,000 attendees and features 300 companies. Can-Fite plans to update on its advanced pipeline, including Phase III trials for rheumatoid arthritis, psoriasis, and liver cancer, alongside new studies for COVID-19 and NAFLD/NASH. Investors can register to view the presentation online.